NCT01712334View on ClinicalTrials.gov

A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eRapid Nebulizer System in Patients With Cystic Fibrosis

PHASE4CompletedINTERVENTIONAL

Enrollment

99

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions

Cystic Fibrosis

Interventions

DRUG

dornase alfa [Pulmozyme®]

Inhaled once daily by Pari eRapid nebulizer.

DRUG

dornase alfa [Pulmozyme®]

Inhaled once daily by Pari LC Plus jet nebulizer.

Trial Locations (16)

4102

Portland

14618

Rochester

27710

Durham

29425

Charleston

44106

Cleveland

44308

Akron

57104

Sioux Falls

72202

Little Rock

77030

Houston

84132

Salt Lake City

85016

Phoenix

98105

Seattle

02115

Boston

03756

Lebanon

07740

Long Branch

37232-9119

Nashville

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

lead

Genentech, Inc.

INDUSTRY